Recombinant Human IL-28 R alpha/IFN-lambda R1 Fc Chimera, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human IL-28 R alpha/IFN-lambda R1 Fc Chimera, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. In a 100 μL reaction mixture containing rhIL-28 R alpha /Fc Chimera at 1 μg/mL and rhIL-28A (Catalog # 1587-IL) dilutions at 1-1000 ng/mL, the concentration of rhIL-28A that produces 50% of the optimal binding response is found to be approximately 40-200 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human IL-28 R alpha/IFN-lambda R1 protein

  Human IL-28 R alpha (Arg21 - Ala228) Accession # Q8IU57

  IEGRMD

  Human IgG 1 (Pro100 - Lys330)

  N-terminus

  C-terminus

• Accession #: Q8IU57
• N-terminal Sequence: Arg21
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: IFNLR1
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 50.2 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 65-75 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-28 R alpha/IFN-lambda R1 Fc Chimera, CF

• class II cytokine receptor CRF2/12
• CRF2/12
• CRF2-12
• Cytokine receptor class-II member 12
• Cytokine receptor family 2 member 12
• IFN-lambda R1
• IFN-lambda receptor 1
• IFN-lambda-R1
• IFNLR
• IFNLR1
• IL-28 R alpha
• IL-28 receptor subunit alpha
• IL28R alpha
• IL-28R1
• IL28RA
• IL-28Ra
• IL-28R-alpha
• Interferon lambda receptor 1
• interferon lambda, receptor 1
• interleukin 28 receptor A
• interleukin 28 receptor, alpha (interferon, lambda receptor)
• interleukin 28 receptor, alpha
• interleukin or cytokine receptor 2
• interleukin-28 receptor subunit alpha
• LICR2
• Likely interleukin or cytokine receptor 2

Background

IL-28 R alpha (IL-28 receptor alpha subunit; also named interferon-lambda R1) is a type I transmembrane glycoprotein that is the cytokine receptor family 2 member 12 (CRF2-12) (1 - 4). It pairs with the IL-10 receptor beta subunit (IL-10 R beta , CRF2-4) to form the IL-28 R (1 - 4). Each subunit of this receptor can interact with the interferon-like cytokines (type III interferons) IL-28A (IFN-lambda 2), IL-28B (IFN-lambda 3) or IL-29 (IFN-lambda 1) (1 - 4). Human IL-28 R alpha cDNA encodes a 520 amino acid (aa) protein with a 20 aa signal peptide, a 208 aa extracellular domain (ECD) with a fibronectin type III motif and four potential N-glycosylation sites, a 21 aa transmembrane sequence, and a proline-rich and acidic 271 aa cytoplasmic domain. Eight isoforms have been sequenced, but their significance is unknown (3, 5). Isoforms of 211 and 244 aa appear to lack transmembrane sequences. These and other isoforms of 491, 437, 322, 283 and 184 aa have alternate N- or C-termini, or lack an internal sequence (aa 268 - 296). The mature human IL-28 R alpha ECD shares 67%, 66%, 78% and 74% aa sequence identity with mouse, rat, canine and bovine IL-28 R alpha , respectively. Some cross-species reactivity has been shown (6). IL-28 R is constitutively expressed in most tissues, but its ligands are mainly produced by antigen presenting cells in response to viruses and their products (2 - 6). Signaling through IL-28 R alpha is similar to that of receptors for type I IFNs, including tyrosine phosphorylation, activation of JAK tyrosine kinases, STAT phosphorylation and formation of the IFN-stimulated gene factor 3 (ISGF-3) transcription factor complex (1 - 7). This signaling pathway induces antiviral activity and upregulates MHC class I antigen expression (2 - 7). Anti-proliferative activity has also been shown for IL-28/IL-28 R (7).

1. Chen, Q. et al. (2006) Vitam. Horm. 74:207.
2. Meager, A. et al. (2005) Cytokine 31:109.
3. Sheppard, P. et al. (2003) Nat. Immunol. 4:63.
4. Kotenko, S.V. et al. (2003) Nat. Immunol. 4:69.
5. Entrez Accession # NP_775088, EAW95113, EAW95115, EAW95116, AAI39723, AAI01409.
6. Lasfar, A. et al. (2006) Cancer Res. 66:4468.
7. Dumoutier, L. et al. (2004) J. Biol. Chem. 279:32269.

Publications for IL-28R alpha/IFN-lambda R1 (5260-MR)(2)

Publications using 5260-MR

• DM Santer, GES Minty, DP Golec, J Lu, J May, A Namdar, J Shah, S Elahi, D Proud, M Joyce, DL Tyrrell, M Houghton Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells PLoS Pathog., 2020-04-30;16(4):e1008515. 2020-04-30 [PMID: 32353085] (Bioassay, Human)
• Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun., 2009-10-01;10(8):702-14. 2009-10-01 [PMID: 19798076] (Bioassay, Human)

Bioinformatics

• Gene Symbol: IFNLR1
• Uniprot:
  • Q8IU57(Human)